Maintenance Pembrolizumab Did Not Improve PFS in Small-Cell Lung Cancer
This video examines a phase II trial that studied maintenance pembrolizumab in extensive-stage small-cell lung cancer.
In this video, Shirish M. Gadgeel, MD, of the University of Michigan, discusses a phase II trial that studied pembrolizumab in the maintenance setting for the treatment of extensive-stage small-cell lung cancer patients.
Gadgeel presented results of the study (abstract 8504) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.